Royalty Pharma Insider Sell: Coyne’s 10‑B‑5‑1 Trades Explained
Royalty Pharma’s CFO’s recent 10‑b‑5‑1 plan sells show routine liquidity moves, not a warning, ahead of Q4 earnings and partnership updates.
4 minutes to read
ROYALTY PHARMA PLC
Royalty Pharma Insider Sale: Urist Marshall’s 20,000‑Share Plan‑Based Sell
Royalty Pharma insider Urist Marshall sells 20,000 shares near $40.78, reflecting a structured plan‑based move amid a Teva partnership that could boost royalties and stock upside.
3 minutes to read